Amgen, Cytokinetics Announce Heart Drug Alliance

Amgen and Cytokinetics announced a collaboration to develop heart failure drugs that could yield smaller Cytokinetics more than $600 million depending on development success.


Cytokinetics is receiving an up-front fee of $42 million. In addition, Amgen has purchased nearly 3.5 million shares of Cytokinetics at $9.47 a share, or an aggregate price of about $33 million. Cytokinetics shares closed last Friday at $7.48.

Amgen gained an option to participate in development and commercialization of Cytokinetics' lead drug candidate arising from the heart-failure program, CK-1827452, which recently completed two Phase 1 clinical trials.

Cytokinetics also may receive milestone payments of up to $600 million on CK-1827452 and other products arising from the research as well as royalties, the companies said.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • CNBC's Jackie DeAngelis reports gold has hit its lowest level since June, and crude oil dropped $3.08, closing at $92.88 a barrel as traders say geopolitics appears manageable driving prices lower.

  • Discussing the short-term decline in energy prices and how it impacts the equity market, with Lindsey Piegza, Sterne Agee; Hugh Anderson, HighTower; Hank Smith, Haverford Investments; and CNBC's Rick Santelli.

  • Brian Boyle, Boyle Capital president, sees huge opportunity at AIG. Barry James, James Advantage Funds, shares his top stock picks.